Context Therapeutics licenses Nectin-4 x CD3 TCE bispecific from BioAtla for up to $133.5M

Context Therapeutics Inc.

$15M upfront/near-term plus up to $118.5M milestones and tiered royalties on net sales.
CT-202 (formerly BA3362) IND filing expected mid-2026; Context to fund all development.
Cash runway into 2027 covering CTIM-76 and CT-95 Phase 1 trials plus CT-202 IND expenses.
First CTIM-76 patient dosing expected Oct/Nov 2024; initial dose escalation data 1H 2026.
CT-95 Phase 1 initial dose escalation data expected mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.